ERBB2 and endometrial cancer: Firstly, there are promising data on ADCs targeting HER2, particularly trastuzumab deruxtecan (T-DXd), which has shown positive results in terms of response rates, particularly in cases of serous subtype of endometrial cancer with HER2 expression.